Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Degenerative disc disease — master index

Last curated: 2026-10-28 · status: sweeps of 2026-09-30, 2026-10-14, 2026-10-21 and 2026-10-28 pending independent audit

The condition in five sentences. Degenerative disc disease (DDD) describes age-, inheritance- and exposure-associated intervertebral-disc structural change, but the label is not itself a pain diagnosis because degeneration is common in asymptomatic adults (Brinjikji 2015, PMID 25430861). Disc findings are more prevalent in people with low-back pain than controls, yet association does not identify a painful level or establish causality (Brinjikji 2015, PMID 26359154). Genetics, endplate transport, smoking, metabolic factors, matrix loss, inflammation, senescence and altered mechanics interact, replacing a simple “wear and tear” model (Battié 2009, PMID 19111259; Urban 2007, PMID 17260404; Mohd Isa 2022, PMID 36613651). Initial care for nonspecific or suspected disc-associated low-back pain is education and active nonoperative management; fusion, disc replacement, basivertebral ablation and intradiscal therapies apply only to selected phenotypes with very different evidence maturity (Qaseem 2017, PMID 28192789; Fischgrund 2018, PMID 29423885; Furunes 2018, PMID 29794581). Its deliberate sibling is spinal stenosis: degeneration can contribute to stenosis, but radiographic disc change, discogenic pain and neural compression are not interchangeable.

Start here: Overview · Research frontier: Open questions · Growth history: Curation log

Build at a glance

Artifact Completed scope
Canonical wiki pages 18/18; 12 curated, 6 updated pages draft pending independent audit
Unique PubMed records in bibliography 369 (348 previously audited; 21 live-verified sweep additions)
Live-verified ClinicalTrials.gov records tracked 54
Landmark evidence notes 6
Guideline/policy documents tracked 19, plus one companion summary and one reporting standard
Quantitative statistics rows 174 data rows
Patient-voice layer 4 files; 12 verified organization/resource entries
Open questions 32 (20 Tier 1; 12 Tier 2)
Unconnected-dot hypotheses 20

Reading paths

Need Suggested path
Understand what DDD does—and does not—mean Overview → Nomenclature and diagnostic validity → Imaging and grading
Understand biology and risk Disc anatomy and biomechanics → Cellular and molecular degeneration → Genetics and environmental risk
Work through a clinical presentation Discogenic pain and differential → Red flags and safety → Conservative treatment
Compare procedures and surgery Injections and ablative procedures → Fusion and disc replacement → Outcomes and measurement
Assess emerging treatments Regenerative and biologic therapy → Biomarkers → Clinical-trials landscape
See policy and lived-experience context Guidelines → Patient experience and advocacy → Patient-voice themes

Pages

File Scope Status
overview.md Nomenclature, imaging–pain gap, biology and treatment map curated
nomenclature-and-diagnostic-validity.md DDD label, discogenic pain, nonspecific back pain and coding curated
epidemiology-and-natural-history.md Age patterns, progression, symptoms and global low-back burden curated
disc-anatomy-and-biomechanics.md Nucleus, annulus, endplate, loading, nutrition and failure curated
cellular-and-molecular-degeneration.md Matrix loss, inflammation, senescence, oxidative stress and innervation curated
genetics-and-environmental-risk.md Twin evidence, variants, smoking, obesity, work and injury curated
imaging-and-grading.md MRI features, Pfirrmann, Modic change and asymptomatic findings curated
discogenic-pain-and-differential.md Phenotyping, referred/radicular pain, hip/SI and visceral mimics curated
conservative-treatment.md Education, exercise, rehabilitation, medicines and behavioral care draft
injections-and-ablative-procedures.md Intradiscal approaches, epidural use and basivertebral ablation draft
fusion-and-disc-replacement.md Indications, comparative trials, adjacent disease and reoperation curated
regenerative-and-biologic-therapy.md Cells, growth factors, hydrogels, gene therapy and trial quality draft
outcomes-and-measurement.md Pain, ODI, function, return to work and imaging endpoints curated
guidelines.md International recommendations, agreements and disagreements draft
biomarkers.md Inflammatory, imaging, biomechanical and molecular candidates curated
clinical-trials-landscape.md Rehabilitation, procedures, devices and regeneration trials draft
patient-experience-and-advocacy.md Diagnostic labeling, fear, work, access and patient priorities draft
red-flags-and-safety-concerns.md Cancer, infection, fracture, cauda equina, myelopathy and procedural risk curated

Literature layer

Artifact Contents
BIBLIOGRAPHY.md Deduplicated bibliography of 369 PMIDs, including explicitly labeled literature-only additions
Landmark notes Structured notes on asymptomatic imaging, Pfirrmann grading, twin evidence, STarT Back, BVN ablation and disc progenitor cells
Guideline registry Nineteen guideline/policy documents plus a companion summary and a reporting standard, status, scope and disagreements
Statistics Source-, year-, population- and method-qualified quantitative claims
Patient voice Methods, themes, organizations, sources and geographic/selection limitations

Curation state

The baseline condition was independently audited on 2026-08-30. The 2026-09-30 sweep updated four wiki pages, which are now draft pending the separate auditor; the other 14 retain their previous curated status. Ten PubMed records and one previously untracked trial were added, trial status/results were refreshed, and guideline, statistics, patient-resource and open-question layers were updated. New clinical claims were checked against live abstracts or registry records; the new acute guideline's recommendation-level extraction remains outstanding. No landmark deep note was warranted. See the log and sweep evidence for scope, queries and follow-ups.

The 2026-10-14 sweep (Claude) corrected the registry's stale NICE NG59 status: NG59 was last updated on 29 July 2026, when its psychological-therapy recommendations were withdrawn. It also added the 2026 Chinese multidisciplinary consensus, with recommendation wording verified from the full text, and a meta-analysis of 11 PRP RCTs that found no significant pooled benefit at very low certainty. Two trial registrations were added: the terminated VIA Disc NP registry and the recruiting Intracept real-world registry. Guidelines, injections, trials and regenerative pages are draft pending audit. See the log and sweep evidence.

The 2026-10-21 sweep added the previously missed Cochrane lumbar-support review and a broad sham-comparison systematic review to the bibliography for full-text appraisal and incorporated ISSLS VERTEBRA into the regenerative-trial reporting framework. All 51 tracked trial records were re-fetched; two previously registered studies, ABBA and CLARITY, were added. BackCare’s booklet landing page is now available. No new burden estimate or landmark note was warranted. See the log and sweep evidence; the two edited wiki pages remain draft.

The 2026-10-28 sweep added a DDD-specific preoperative coping/affect cohort (Rejner 2026, PMID 42941526; full text) and a PLoS Medicine cost-effectiveness systematic review of guideline-recommended LBP care (Mathieson 2026, PMID 42945153; full text). All 53 tracked trial records were re-fetched with no status or results change; NCT07895225 (PRP versus nucleus-pulposus graft, not yet recruiting) was added. No new society guideline or Cochrane DDD/LBP review was found in PubMed for this window. No landmark deep note was warranted. See the log and sweep evidence. Edited wiki pages are draft.